About Us
We are transforming the treatment of neurological disease with our genetic medicines that are designed to overcome the limitations of current treatments.
Our Mission
Central nervous system (CNS) disorders remain the world's leading cause of disability, and account for more hospitalisations and prolonged care then almost all other diseases combined.
​
With the rapid growth of genetic medicines like ASOs, siRNA, and mRNA, further optimization is required for update and utilisation into target cells.​
​
At Centron Bio, we are dedicated to creating safe and effective drug delivery platforms that are rationally-designed to optimize delivery, utilization, and safety of brain and muscle delivered medicines.
​​
Dr James Tran, PhD
CEO
​
​
​
​
​
​
​Dr Tran has a track record in business development at AdAlta (ASX:1AD) and experience across private biotech ventures, with a foundation in translational neuroscience research.
​
Dr Tran has a strong focus on accelerating growth and transformational leadership and is versed in early-stage biotechnology development having lead international business development programs between Australia, Asia and the US.
​
Associate Professor
Fazel Shabanpoor
CSO, Director
Co-founder
​
​​​
​​​
​​​
​​
​
Associate Professor Shabanpoor is a medicinal biochemist specialising in peptide and oligonucleotide drug development. He completed his post-doctoral training at the MRC Laboratory of Molecular Biology in Cambridge and the Department of Physiology, Anatomy and Genetics at the University of Oxford.
​
During his time in the UK, he focused on the development of therapeutic peptides and antisense oligonucleotides (ASOs) for the treatment of neurodegenerative diseases. Since his return to Melbourne, he has established peptide and antisense drug development platforms at The Florey.
​
Associate Professor Shabanpoor is passionate about developing groundbreaking solutions for the treatment of complex CNS disorders.
